<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996605</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00025901</org_study_id>
    <nct_id>NCT01996605</nct_id>
  </id_info>
  <brief_title>Efficacy of Spinal Oxytocin in Healthy Volunteers</brief_title>
  <official_title>Efficacy of Intrathecal Oxytocin in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of intrathecal oxytocin on areas and&#xD;
      intensity of hyperalgesia and allodynia induced by topical capsaicin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: There is a strong experimental basis to support the study of oxytocin by the spinal&#xD;
      route for analgesia in humans. Oxytocin containing cells in the dorsal parvocellular division&#xD;
      of the paraventricular nucleus (PVN) project to the spinal cord (1). Noxious stimulation&#xD;
      activates these cells via the A1 noradrenergic relay in the pons (2) and produces analgesia&#xD;
      by spinal release of oxytocin, since intrathecal injection of an oxytocin receptor antagonist&#xD;
      worsens pain behaviors from peripheral inflammation (3). Direct electrical stimulation of the&#xD;
      PVN reduces dorsal horn neuronal responses to noxious stimulation, and this is blocked by&#xD;
      administration of sequestering antibody for oxytocin (4). Similarly, direct electrical&#xD;
      stimulation of the PVN reduces behavioral sensitivity in a model of chronic neuropathic pain,&#xD;
      and this effect is blocked by an oxytocin receptor antagonist (5). Intrathecal injection of&#xD;
      oxytocin in normal rats reduces dorsal horn neuronal responses to noxious stimuli (6) as well&#xD;
      as behavioral responses to noxious thermal (3), mechanical (3), and chemical (7) stimuli.&#xD;
      Finally, intrathecal injection of oxytocin in rat models of chronic pain also reduces dorsal&#xD;
      horn neuronal responses to sensory stimulation (6) as well as behavioral responses to thermal&#xD;
      (5) and mechanical (7) stimuli.&#xD;
&#xD;
      Rationale: We anticipate that oxytocin will be effective after spinal injection in humans&#xD;
      against chemical induced hypersensitivity states.&#xD;
&#xD;
      Objectives: Determine the effect of intrathecal oxytocin on areas and intensity of&#xD;
      hyperalgesia and allodynia induced by topical capsaicin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperalgesia</measure>
    <time_frame>105 minutes</time_frame>
    <description>The area of hyperalgesia after the first skin heating following topical capsaicin.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Oxytocin 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 15 mcg injected spinally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 150 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 150 mcg injected spinally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preservative free normal saline injected spinally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 15 mcg</intervention_name>
    <description>Oxytocin 15 mcg will be administered spinally</description>
    <arm_group_label>Oxytocin 15 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 150 mcg</intervention_name>
    <description>Oxytocin 150 mcg will be administered spinally</description>
    <arm_group_label>Oxytocin 150 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo will be administered spinally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy&#xD;
&#xD;
          -  weight &lt; 240 pounds&#xD;
&#xD;
          -  American Society of Anesthesiology Category 1 or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to oxytocin or lidocaine&#xD;
&#xD;
          -  allergy to chilli peppers&#xD;
&#xD;
          -  Females: active gynecological disease such as uterine fibroids or ongoing bleeding&#xD;
&#xD;
          -  Pregnancy or currently breastfeeding&#xD;
&#xD;
          -  Females that have delivered a baby within 2 years of study&#xD;
&#xD;
          -  Taking prescription medications (exception: oral birth control medication)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Eisenach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Curry, RN</last_name>
      <phone>336-716-4294</phone>
      <email>recurry@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>James C Eisenach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

